Possible scenario
Reshoring Plan Accepted
42% Chance
Investors view Becton Dickinson's $3 billion US manufacturing investment as a credible response to tariff risk, Buy American rules, and recent hospital supply disruptions. The plan is seen as improving supply reliability for core medical products while strengthening BD's position with US health systems and government buyers.
Secondary impacts
- Healthcare +0.4%
- Industrials +0.2%
Tickers
- NB+4.3%
- BDX+1.4%
- BAX-0.4%
Portfolio impact
S&P 500+0.1%
Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.
Keeping an eye on this scenario?
Tilt can alert you when its probability or impact shifts, or send you a recommendation when it crosses a threshold.